Table 1 Patient characteristics
Variable | All (n = 393) |
|---|---|
Age, years | 56.0 (48.0–65.0) |
Male, n (%) | 287 (73.0%) |
Weight, kg | 70.0 (60.0–75.0) |
BMI, kg/m2 | 23.7 (21.2–25.7) |
ICU admission, n (%) | 361 (91.9%) |
Mechanical ventilation, n (%) | 269 (68.4%) |
SOFA score | 8.0 (6.0–10.0) |
APACHE II score | 18.0 (13.0–23.0) |
Comorbidities, n (%) | |
Diabetes | 127 (32.3%) |
Malignancy | 53 (13.5%) |
Hypertension | 162 (41.2%) |
Heart disease | 97 (24.7%) |
Stroke | 92 (23.4%) |
Sepsis | 186 (47.3%) |
Septic shock | 153 (38.9%) |
Pathogen, n (%) | |
Klebsiella pneumoniae | 177 (42.7%) |
Acinetobacter baumannii | 168 (40.5%) |
Pseudomonas aeruginosa | 44 (10.6%) |
Escherichia coli | 17 (4.1%) |
Pneumogenic klebsiella | 9 (2.2%) |
Polymyxin B treatment | |
Duration days | 13.0 (8.0–18.0) |
Daily dose, mg | 150.0 (100.0–150.0) |
Daily dose/weight, mg/kg/day | 2.12 (1.67–2.50) |
Concomitant antibiotics, n (%) | |
Carbapenem | 209 (53.2%) |
Cephalosporin | 184 (46.8%) |
Tigecycline | 136 (34.6%) |
Rifampicin | 25 (6.4%) |
Aminoglycosides | 12 (3.1%) |
Fosfomycin | 8 (2.0%) |
Aztreonam | 7 (1.8%) |
Laboratory data | |
GFR, mL/min·1.73m2 | 101.2 (71.3–118.3) |
Scr, µmol/L | 62.0 (45.3–93.4) |
Albumin, g/L | 30.0 (27.2–34.9) |
White blood cell, 109/L | 11.2 (8.0–15.7) |
Platelets, 109/L | 168.5 (88.0–275.3) |
C-reactive protein, μg/L | 72.2 (34.6–140.0) |
Procalcitonin, ng/mL | 1.0 (0.4–3.6) |
Concomitant nephrotoxic drugs, n (%) | |
Vancomycin | 83 (21.1%) |
Aminoglycoside | 12 (3.1%) |
Amphotericin B | 35 (8.9%) |
Furosemide | 154 (39.2%) |
Vasoactive drugs | 195 (50.5%) |
Immunosuppressant | 32 (8.1%) |
Use of nephrotoxic drugsa | 289 (73.5%) |
AUCss,24 h, mg h/L | 58.5 (40.6–77.2) |
C0h, mg L−1 | 1.24 (0.74–1.93) |